Latest News

Axsome Submits sNDA for AXS-05 to Treat Agitation in Alzheimer Disease / image credit ©David/stock.adobe.com
Axsome Submits sNDA for AXS-05 to Treat Agitation in Alzheimer Disease

November 7th 2025

Submission of the sNDA suggests a potential FDA decision on the dextromethorphan-bupropion combination sometime during the first quarter of 2026.

Nonstimulant Pharmacotherapy for ADHD: A Clinical Update for Primary Care / image credit: ©Joel bubble ben/AdobeStock
Nonstimulant Pharmacotherapy for ADHD: A Clinical Update for Primary Care

November 4th 2025

FAQs On The Critical Window Hypothesis for Hormone Therapy's Neuroprotective Effects / image credit ©DigitalDruid generated by AI/stock.adobe.com
FAQs On The Critical Window Hypothesis for Menopausal Hormone Therapy's Neuroprotective Effects

October 29th 2025

Investigational Oral Agent Slows Brain Atrophy and Cognitive Decline in APOE4 Homozygotes with Early AD
Investigational Oral Agent ALZ-801 Slows Brain Atrophy and Cognitive Decline in APOE4 Homozygotes with Early AD

October 28th 2025

Plasma Biomarkers Achieve High Accuracy for Confirmatory Aβ Positivity in Disease-Modifying Therapy Eligibility / image credit courtesy of CISRO
Plasma Biomarkers Achieve High Accuracy for Confirmatory Aβ Positivity in Eligibility Test for DMT in Alzheimer Disease

October 21st 2025

Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.